Editorial
doi: 10.1161/CIRCULATIONAHA.111.049544.
Is diabetes the achilles' heel of limus-eluting stents?
- PMID: 21859980
- DOI: 10.1161/CIRCULATIONAHA.111.049544
Item in Clipboard
Editorial
Is diabetes the achilles' heel of limus-eluting stents?
Circulation.
.
No abstract available
Comment on
-
Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.Circulation. 2011 Aug 23;124(8):893-900. doi: 10.1161/CIRCULATIONAHA.111.031070. Epub 2011 Aug 8. Circulation. 2011. PMID: 21824922
Similar articles
-
Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.Circulation. 2011 Aug 23;124(8):893-900. doi: 10.1161/CIRCULATIONAHA.111.031070. Epub 2011 Aug 8. Circulation. 2011. PMID: 21824922
-
Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.Circulation. 2011 Aug 23;124(8):886-92. doi: 10.1161/CIRCULATIONAHA.110.015453. Epub 2011 Aug 1. Circulation. 2011. PMID: 21810659 Clinical Trial.
-
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).J Am Coll Cardiol. 2010 Dec 14;56(25):2084-9. doi: 10.1016/j.jacc.2010.10.006. J Am Coll Cardiol. 2010. PMID: 21144968 Clinical Trial.
-
Current status of the Xience V® everolimus-eluting coronary stent system.Expert Rev Cardiovasc Ther. 2010 Oct;8(10):1363-74. doi: 10.1586/erc.10.127. Expert Rev Cardiovasc Ther. 2010. PMID: 20936921 Review.
-
New-generation drug-eluting stents: focus on Xience V® everolimus-eluting stent and Resolute® zotarolimus-eluting stent.J Interv Cardiol. 2013 Jun;26(3):278-86. doi: 10.1111/joic.12028. Epub 2013 Apr 22. J Interv Cardiol. 2013. PMID: 23607275 Review.
Cited by
-
Evaluation of Ultrathin Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents in an All-Comers Patient Population: 1-Year Results of the S-FLEX Slovakia Registry.Anatol J Cardiol. 2024 Mar;28(3):142-149. doi: 10.14744/AnatolJCardiol.2023.3801. Anatol J Cardiol. 2024. PMID: 38419511 Free PMC article.
-
Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.J Am Heart Assoc. 2019 Nov 19;8(22):e013607. doi: 10.1161/JAHA.119.013607. Epub 2019 Nov 7. J Am Heart Assoc. 2019. PMID: 31696762 Free PMC article. Clinical Trial.
-
Efficacy of Zotarolimus-Eluting Stents in Treating Diabetic Coronary Lesions: An Optical Coherence Tomography Study.Adv Ther. 2020 Apr;37(4):1579-1590. doi: 10.1007/s12325-020-01273-6. Epub 2020 Mar 7. Adv Ther. 2020. PMID: 32146703
-
Clinical Outcomes in Diabetic Patients Who Underwent Percutaneous Coronary Intervention during the Plain Old Balloon Angioplasty (POBA)-, Bare Metal Stents (BMS)- and Drug-eluting Stents (DES)-eras from 1984 to 2010.Intern Med. 2017;56(1):1-9. doi: 10.2169/internalmedicine.56.7423. Epub 2017 Jan 1. Intern Med. 2017. PMID: 28049984 Free PMC article.
-
Everolimus-eluting stents in interventional cardiology.Vasc Health Risk Manag. 2012;8:393-404. doi: 10.2147/VHRM.S23388. Epub 2012 Jun 27. Vasc Health Risk Manag. 2012. PMID: 22910420 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
